Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2007 4
2008 4
2009 2
2010 2
2012 2
2013 1
2014 1
2015 1
2016 2
2017 2
2018 1
2019 1
2020 3
2021 1
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Kawabata R, Chin K, Takahari D, Hosaka H, Muto O, Shindo Y, Nagata N, Yabusaki H, Imamura H, Endo S, Kashiwada T, Nakamura M, Hihara J, Kobayashi M, Sagawa T, Saito S, Sato A, Yamada T, Okano N, Shimada K, Matsushima M, Kataoka M, Matsumoto S, Goto M, Kotaka M, Shiraishi T, Yamai H, Nagashima F, Ishizuka N, Yamaguchi K. Kawabata R, et al. Among authors: muto o. Gastric Cancer. 2023 Nov;26(6):1020-1029. doi: 10.1007/s10120-023-01423-z. Epub 2023 Aug 23. Gastric Cancer. 2023. PMID: 37610558 Free PMC article. Clinical Trial.
Retrodental mass in rheumatoid arthritis.
Yonezawa I, Okuda T, Won J, Sakoda J, Nakahara D, Nojiri H, Muto O, Momomura R, Kaneko K. Yonezawa I, et al. Among authors: muto o. J Spinal Disord Tech. 2013 Apr;26(2):E65-9. doi: 10.1097/BSD.0b013e3182621a05. J Spinal Disord Tech. 2013. PMID: 22688616
Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.
Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y. Nakamura M, et al. Among authors: muto o. BMC Cancer. 2022 Dec 16;22(1):1322. doi: 10.1186/s12885-022-10403-y. BMC Cancer. 2022. PMID: 36526992 Free PMC article.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: muto o. Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086. Oncologist. 2022. PMID: 35579511 Free PMC article. Clinical Trial.
Two autopsy cases of desmoplastic small round cell tumor.
Yamamoto Y, Nishijima-Matsunobu A, Hiroshima Y, Enomoto K, Inoue M, Muto O, Suzuki M, Nanjo H, Shibata H, Omori Y. Yamamoto Y, et al. Among authors: muto o. Pathol Int. 2020 Mar;70(3):171-178. doi: 10.1111/pin.12897. Epub 2020 Jan 15. Pathol Int. 2020. PMID: 31944485
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Among authors: muto o. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article.
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y. Harada K, et al. Among authors: muto o. J Clin Med. 2023 Feb 17;12(4):1596. doi: 10.3390/jcm12041596. J Clin Med. 2023. PMID: 36836140 Free PMC article.
34 results